Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV-Reference-Cited by-同舟云学术

Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV

Published:2015-12-25 Issue:4 Volume:36 Page:515-521
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Saab Sammy¹,Gonzalez Yuri S.²,Huber Caroline³,Wang Alice²,Juday Timothy²

Affiliation:

1. Pfleger Liver Institute; University of California; Los Angeles California USA

2. AbbVie Inc.; North Chicago Illinois USA

3. Precision Health Economics; Los Angeles California USA

Funder

AbbVie

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13033/fullpdf

Reference29 articles.

1. Hepatitis C virus treatment pre-and post-liver transplantation;Roche;Liver Int,2012

2. Health Resources and Services Administration Transplant: organ by diagnosis, transplant year (2013-2014) http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp

3. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma;Biggins;Liver Transpl,2012

4. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment;Berenguer;J Hepatol,2013

5. Management of post transplant hepatitis C in the direct antiviral agents era;Coilly;Hepatol Int,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral proteases as therapeutic targets;Molecular Aspects of Medicine;2022-12

2. Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review;Antiviral Therapy;2019

3. 100% Sustained Virological Response and Fibrosis Improvement in Real-Life Use of Direct Acting Antivirals in Genotype-1b Recurrent Hepatitis C following Liver Transplantation;Journal of Gastrointestinal and Liver Diseases;2018-06-30

4. Elimination of Hepatitis C in Liver Transplant Recipients;Journal of Clinical and Translational Hepatology;2018-06-08

5. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C;Journal of Clinical and Translational Hepatology;2017-05-14